BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Boutros C, Gary M, Baldwin K, Somasundar P. Gallbladder cancer: past, present and an uncertain future. Surg Oncol. 2012;21:e183-e191. [PMID: 23025910 DOI: 10.1016/j.suronc.2012.08.002] [Cited by in Crossref: 88] [Cited by in F6Publishing: 77] [Article Influence: 9.8] [Reference Citation Analysis]
Number Citing Articles
1 Dasari BVM, Ionescu MI, Pawlik TM, Hodson J, Sutcliffe RP, Roberts KJ, Muiesan P, Isaac J, Marudanayagam R, Mirza DF. Outcomes of surgical resection of gallbladder cancer in patients presenting with jaundice: A systematic review and meta-analysis. J Surg Oncol. 2018;118:477-485. [PMID: 30259519 DOI: 10.1002/jso.25186] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
2 Xu S, Zhan M, Wang J. Epithelial-to-mesenchymal transition in gallbladder cancer: from clinical evidence to cellular regulatory networks. Cell Death Discov 2017;3:17069. [PMID: 29188076 DOI: 10.1038/cddiscovery.2017.69] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
3 Sirivatanauksorn V, Dumronggittigule W, Dulnee B, Srisawat C, Sirivatanauksorn Y, Pongpaibul A, Masaratana P, Somboonyosdech C, Sripinitchai S, Kositamongkol P, Mahawithitwong P, Tovikkai C, Sangserestid P, Limsrichamrern S. Role of stratifin (14-3-3 sigma) in adenocarcinoma of gallbladder: A novel prognostic biomarker. Surg Oncol 2020;32:57-62. [PMID: 31751820 DOI: 10.1016/j.suronc.2019.10.022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
4 Shi Y, Sun L, Zhang R, Hu Y, Wu Y, Dong X, Dong D, Chen C, Geng Z, Li E, Fan Y. Thrombospondin 4/integrin α2/HSF1 axis promotes proliferation and cancer stem-like traits of gallbladder cancer by enhancing reciprocal crosstalk between cancer-associated fibroblasts and tumor cells. J Exp Clin Cancer Res 2021;40:14. [PMID: 33407730 DOI: 10.1186/s13046-020-01812-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Li M, Chen W, Zhang H, Zhang Y, Ke F, Wu X, Zhang Y, Weng M, Liu Y, Gong W. MiR-31 regulates the cisplatin resistance by targeting Src in gallbladder cancer. Oncotarget 2016;7:83060-70. [PMID: 27825112 DOI: 10.18632/oncotarget.13067] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
6 Lu W, Hu Y, Ma Q, Zhou L, Jiang L, Li Z, Zhao S, Xu Y, Shi W, Li S, Liu Y. miR-223 increases gallbladder cancer cell sensitivity to docetaxel by downregulating STMN1. Oncotarget 2016;7:62364-76. [PMID: 27577078 DOI: 10.18632/oncotarget.11634] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
7 Dixit R, Raza M, Kumar M, Basu S, Shukla VK. Expression Analysis of Survivin and XIAP in Gallbladder Cancer: a Case-control Study in Indo-Gangetic Plain. J Gastrointest Canc 2018;49:487-92. [DOI: 10.1007/s12029-017-0008-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Zhang M, Gong W, Zuo B, Chu B, Tang Z, Zhang Y, Yang Y, Zhou D, Weng M, Qin Y, Ma M, Jiang A, Ma F, Quan Z. The microRNA miR-33a suppresses IL-6-induced tumor progression by binding Twist in gallbladder cancer. Oncotarget 2016;7:78640-52. [PMID: 27769047 DOI: 10.18632/oncotarget.12693] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
9 Melillo A, Linden K, Spitz F, Atabek U, Gaughan J, Hong YK. Disparities in Treatment for Gallbladder Carcinoma: Does Treatment Site Matter? J Gastrointest Surg 2020;24:1071-6. [PMID: 32095928 DOI: 10.1007/s11605-019-04389-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
10 Pang Q, Zhang LQ, Wang RT, Bi JB, Zhang JY, Qu K, Liu SS, Song SD, Xu XS, Wang ZX. Platelet to lymphocyte ratio as a novel prognostic tool for gallbladder carcinoma. World J Gastroenterol. 2015;21:6675-6683. [PMID: 26074706 DOI: 10.3748/wjg.v21.i21.6675] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
11 Wang H, Dong F, Wang Y, Wang X, Hong D, Liu Y, Zhou J. Betulinic acid induces apoptosis of gallbladder cancer cells via repressing SCD1. Acta Biochim Biophys Sin (Shanghai) 2020;52:200-6. [PMID: 31915810 DOI: 10.1093/abbs/gmz148] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
12 Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol. 2014;6:99-109. [PMID: 24634588 DOI: 10.2147/clep.s37357clep-6-099] [Reference Citation Analysis]
13 Yang G, Qin H, Raza A, Saukel GW, Solomon N, Michelotti M, Raghavan R. Pyloric gland adenoma of gallbladder-reports of two cases and a brief review of literature. J Gastrointest Oncol. 2016;7:S81-S87. [PMID: 27034818 DOI: 10.3978/j.issn.2078-6891.2015.015] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
14 Wang XA, Xiang SS, Li HF, Wu XS, Li ML, Shu YJ, Zhang F, Cao Y, Ye YY, Bao RF. Cordycepin induces S phase arrest and apoptosis in human gallbladder cancer cells. Molecules. 2014;19:11350-11365. [PMID: 25090123 DOI: 10.3390/molecules190811350] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
15 Zhao X, Xu M, Cai Z, Yuan W, Cui W, Li MD. Identification of LIFR, PIK3R1, and MMP12 as Novel Prognostic Signatures in Gallbladder Cancer Using Network-Based Module Analysis. Front Oncol 2019;9:325. [PMID: 31119098 DOI: 10.3389/fonc.2019.00325] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
16 Li M, Zhang Z, Li X, Ye J, Wu X, Tan Z, Liu C, Shen B, Wang XA, Wu W, Zhou D, Zhang D, Wang T, Liu B, Qu K, Ding Q, Weng H, Ding Q, Mu J, Shu Y, Bao R, Cao Y, Chen P, Liu T, Jiang L, Hu Y, Dong P, Gu J, Lu W, Shi W, Lu J, Gong W, Tang Z, Zhang Y, Wang X, Chin YE, Weng X, Zhang H, Tang W, Zheng Y, He L, Wang H, Liu Y, Liu Y. Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway. Nat Genet. 2014;46:872-876. [PMID: 24997986 DOI: 10.1038/ng.3030] [Cited by in Crossref: 202] [Cited by in F6Publishing: 195] [Article Influence: 28.9] [Reference Citation Analysis]
17 Vega-Vela NE, Osorio D, Avila-Rodriguez M, Gonzalez J, García-Segura LM, Echeverria V, Barreto GE. L-Type Calcium Channels Modulation by Estradiol. Mol Neurobiol 2017;54:4996-5007. [PMID: 27525676 DOI: 10.1007/s12035-016-0045-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 4.6] [Reference Citation Analysis]
18 Li M, Zhang S, Wang Z, Zhang B, Wu X, Weng H, Ding Q, Tan Z, Zhang N, Mu J. Prognostic significance of nemo-like kinase (NLK) expression in patients with gallbladder cancer. Tumour Biol. 2013;34:3995-4000. [PMID: 23857283 DOI: 10.1007/s13277-013-0988-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
19 Cai YL, Lin YX, Jiang LS, Ye H, Li FY, Cheng NS. A Novel Nomogram Predicting Distant Metastasis in T1 and T2 Gallbladder Cancer: A SEER-based Study. Int J Med Sci 2020;17:1704-12. [PMID: 32714073 DOI: 10.7150/ijms.47073] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Li M, Zhang F, Wang X, Wu X, Zhang B, Zhang N, Wu W, Wang Z, Weng H, Liu S, Gao G, Mu J, Shu Y, Bao R, Cao Y, Lu J, Gu J, Zhu J, Liu Y. Magnolol inhibits growth of gallbladder cancer cells through the p53 pathway. Cancer Sci 2015;106:1341-50. [PMID: 26250568 DOI: 10.1111/cas.12762] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 5.6] [Reference Citation Analysis]
21 Liu Y, Bi T, Yuan F, Gao X, Jia G, Tian Z. S-adenosylmethionine induces apoptosis and cycle arrest of gallbladder carcinoma cells by suppression of JAK2/STAT3 pathways. Naunyn Schmiedebergs Arch Pharmacol 2020;393:2507-15. [PMID: 32219484 DOI: 10.1007/s00210-020-01858-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
22 Li HF, Wang XA, Xiang SS, Hu YP, Jiang L, Shu YJ, Li ML, Wu XS, Zhang F, Ye YY, Weng H, Bao RF, Cao Y, Lu W, Dong Q, Liu YB. Oleanolic acid induces mitochondrial-dependent apoptosis and G0/G1 phase arrest in gallbladder cancer cells. Drug Des Devel Ther 2015;9:3017-30. [PMID: 26109845 DOI: 10.2147/DDDT.S84448] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
23 Li Y, Zhang J, Ma H. Chronic inflammation and gallbladder cancer. Cancer Lett. 2014;345:242-248. [PMID: 23981574 DOI: 10.1016/j.canlet.2013.08.034] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
24 Yang L, Huang S, Ma H, Wu X, Feng F. MicroRNA-125b predicts clinical outcome and suppressed tumor proliferation and migration in human gallbladder cancer. Tumour Biol 2017;39:1010428317692249. [PMID: 28347246 DOI: 10.1177/1010428317692249] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
25 Gu B, Qian L, Yu H, Hu J, Wang Q, Shan J, Shi L, Liu H, Yang Q, Liang X, Cai X, Sun X. Concurrent Chemoradiotherapy in Curatively Resected Gallbladder Carcinoma: A Propensity Score–Matched Analysis. International Journal of Radiation Oncology*Biology*Physics 2018;100:138-45. [DOI: 10.1016/j.ijrobp.2017.09.029] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
26 Fakhri B, Lim KH. Molecular landscape and sub-classification of gastrointestinal cancers: a review of literature. J Gastrointest Oncol. 2017;8:379-386. [PMID: 28736626 DOI: 10.21037/jgo.2016.11.01] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
27 Zhang LQ, Xu XS, Wan Y, Song SD, Wang RT, Chen W, Wang ZX, Chang HL, Wei JC, Dong YF, Liu C. Prognostic implications of estrogen receptor 1 and vascular endothelial growth factor A expression in primary gallbladder carcinoma. World J Gastroenterol 2015;21:1243-50. [PMID: 25632198 DOI: 10.3748/wjg.v21.i4.1243] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
28 Zimmermann A. Adenocarcinoma of the Gallbladder: Risk Factors and Pathogenic Pathways. Tumors and Tumor-Like Lesions of the Hepatobiliary Tract. Cham: Springer International Publishing; 2016. pp. 1-10. [DOI: 10.1007/978-3-319-26587-2_149-1] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
29 Li M, Lu J, Zhang F, Li H, Zhang B, Wu X, Tan Z, Zhang L, Gao G, Mu J, Shu Y, Bao R, Ding Q, Wu W, Dong P, Gu J, Liu Y. Yes-associated protein 1 (YAP1) promotes human gallbladder tumor growth via activation of the AXL/MAPK pathway. Cancer Lett. 2014;355:201-209. [PMID: 25218593 DOI: 10.1016/j.canlet.2014.08.036] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 5.3] [Reference Citation Analysis]
30 Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol 2014;6:99-109. [PMID: 24634588 DOI: 10.2147/CLEP.S37357] [Cited by in Crossref: 109] [Cited by in F6Publishing: 241] [Article Influence: 15.6] [Reference Citation Analysis]
31 Wensheng L, Bo Z, Qiangsheng H, Wenyan X, Shunrong J, Jin X, Quanxing N, Xianjun Y, Xiaowu X. MBD1 promotes the malignant behavior of gallbladder cancer cells and induces chemotherapeutic resistance to gemcitabine. Cancer Cell Int 2019;19:232. [PMID: 31516389 DOI: 10.1186/s12935-019-0948-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Chen M, Cao J, Xiang Y, Ma X, Bai Y, Lai Q, Tong C, Ma Z, Topatana W, Hu J, Li S, Juengpanich S, Yu H, Cai X. Hepatectomy strategy for T2 gallbladder cancer between segment IVb and V resection and wedge resection: A propensity score-matched study. Surgery 2021;169:1304-11. [PMID: 33551070 DOI: 10.1016/j.surg.2020.12.039] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
33 Choi SJ, Kim Y, Jeon J, Gwak HJ, Kim M, Kang K, Kim Y, Jeong J, Jung YK, Lee KG, Choi HS, Jung DH, Lee SG, Lee Y, Shin SJ, Jang K, Rho M, Choi D. Association of Microbial Dysbiosis with Gallbladder Diseases Identified by Bile Microbiome Profiling. J Korean Med Sci 2021;36:e189. [PMID: 34282606 DOI: 10.3346/jkms.2021.36.e189] [Reference Citation Analysis]
34 Huang P, Ke H, Qiu Y, Cai M, Qu J, Leng A. Systematically Characterizing Chemical Profile and Potential Mechanisms of Qingre Lidan Decoction Acting on Cholelithiasis by Integrating UHPLC-QTOF-MS and Network Target Analysis. Evid Based Complement Alternat Med 2019;2019:2675287. [PMID: 30719056 DOI: 10.1155/2019/2675287] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
35 Liang PI, Li CF, Chen LT, Sun DP, Chen TJ, Hsing CH, Hsu HP, Lin CY. BCL6 overexpression is associated with decreased p19 ARF expression and confers an independent prognosticator in gallbladder carcinoma. Tumour Biol. 2014;35:1417-1426. [PMID: 24114011 DOI: 10.1007/s13277-013-1195-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
36 Hu YP, Tan ZJ, Wu XS, Liu TY, Jiang L, Bao RF, Shu YJ, Li ML, Weng H, Ding Q. Triptolide induces s phase arrest and apoptosis in gallbladder cancer cells. Molecules. 2014;19:2612-2628. [PMID: 24566325 DOI: 10.3390/molecules19022612] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
37 Yu J, Shi L, Lin W, Lu B, Zhao Y. UCP2 promotes proliferation and chemoresistance through regulating the NF-κB/β-catenin axis and mitochondrial ROS in gallbladder cancer. Biochem Pharmacol 2020;172:113745. [PMID: 31811866 DOI: 10.1016/j.bcp.2019.113745] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
38 Deng Y, Zhang F, Yu X, Huo CL, Sun ZG, Wang S. Prognostic Value Of Preoperative Systemic Inflammatory Biomarkers In Patients With Gallbladder Cancer And The Establishment Of A Nomogram. Cancer Manag Res 2019;11:9025-35. [PMID: 31695494 DOI: 10.2147/CMAR.S218119] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
39 Barreto SG, Pawar S, Shah S, Talole S, Goel M, Shrikhande SV. Patterns of Failure and Determinants of Outcomes Following Radical Re-resection for Incidental Gallbladder Cancer. World J Surg 2014;38:484-9. [DOI: 10.1007/s00268-013-2266-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
40 Sirohi B, Mitra A, Jagannath P, Singh A, Ramadvar M, Kulkarni S, Goel M, Shrikhande SV. Neoadjuvant chemotherapy in patients with locally advanced gallbladder cancer. Future Oncol. 2015;11:1501-1509. [PMID: 25963427 DOI: 10.2217/fon.14.308] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 6.4] [Reference Citation Analysis]
41 Tao F, Ye MF, Sun AJ, Lv JQ, Xu GG, Jing YM, Wang W. Prognostic significance of nuclear hepatoma-derived growth factor expression in gallbladder cancer. World J Gastroenterol 2014;20:9564-9. [PMID: 25071353 DOI: 10.3748/wjg.v20.i28.9564] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
42 Li M, Shen J, Wu X, Zhang B, Zhang R, Weng H, Ding Q, Tan Z, Gao G, Mu J, Yang J, Shu Y, Bao R, Ding Q, Wu W, Cao Y, Liu Y. Downregulated expression of hepatoma-derived growth factor (HDGF) reduces gallbladder cancer cell proliferation and invasion. Med Oncol. 2013;30:587. [PMID: 23609195 DOI: 10.1007/s12032-013-0587-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
43 Tian YH, Ji X, Liu B, Yang GY, Meng XF, Xia HT, Wang J, Huang ZQ, Dong JH. Surgical treatment of incidental gallbladder cancer discovered during or following laparoscopic cholecystectomy. World J Surg. 2015;39:746-752. [PMID: 25403888 DOI: 10.1007/s00268-014-2864-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
44 Qian L, Li X, Ye P, Wang G, Dai W, Liu Y, Gao Q, Shen G. Oxymatrine induces apoptosis and inhibits invasion in Gallbladder carcinoma via PTEN/PI3K/AKT pathway. Cytotechnology 2018;70:83-94. [PMID: 29170841 DOI: 10.1007/s10616-017-0153-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
45 Lee H, Kwon W, Han Y, Kim JR, Kim S, Jang J. Optimal extent of surgery for early gallbladder cancer with regard to long-term survival: a meta-analysis. J Hepatobiliary Pancreat Sci 2018;25:131-41. [DOI: 10.1002/jhbp.521] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
46 Kessler SM, Lederer E, Laggai S, Golob-Schwarzl N, Hosseini K, Petzold J, Schweiger C, Reihs R, Keil M, Hoffmann J, Mayr C, Kiesslich T, Pichler M, Kim KS, Rhee H, Park YN, Lax S, Obrist P, Kiemer AK, Haybaeck J. IMP2/IGF2BP2 expression, but not IMP1 and IMP3, predicts poor outcome in patients and high tumor growth rate in xenograft models of gallbladder cancer. Oncotarget. 2017;8:89736-89745. [PMID: 29163784 DOI: 10.18632/oncotarget.21116] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
47 Sun DP, Lin CY, Tian YF, Chen LT, Lin LC, Lee SW, Hsing CH, Lee HH, Shiue YL, Huang HY. Clinicopathological significance of HuR expression in gallbladder carcinoma: with special emphasis on the implications of its nuclear and cytoplasmic expression. Tumour Biol. 2013;34:3059-3069. [PMID: 23722602 DOI: 10.1007/s13277-013-0872-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
48 Matsumoto N, Morine Y, Utsunomiya T, Imura S, Ikemoto T, Arakawa Y, Iwahashi S, Saito Y, Yamada S, Ishikawa D, Takasu C, Miyake H, Shimada M. Role of CD151 expression in gallbladder carcinoma. Surgery 2014;156:1212-7. [DOI: 10.1016/j.surg.2014.04.053] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
49 Li H, Zhang Y, Hai J, Wang J, Zhao B, Du L, Geng X. Knockdown of TRIM31 suppresses proliferation and invasion of gallbladder cancer cells by down-regulating MMP2/9 through the PI3K/Akt signaling pathway. Biomedicine & Pharmacotherapy 2018;103:1272-8. [DOI: 10.1016/j.biopha.2018.04.120] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
50 Ouyang B, Pan N, Zhang H, Xing C, Ji W. miR‑146b‑5p inhibits tumorigenesis and metastasis of gallbladder cancer by targeting Toll‑like receptor 4 via the nuclear factor‑κB pathway. Oncol Rep 2021;45:15. [PMID: 33649824 DOI: 10.3892/or.2021.7966] [Reference Citation Analysis]
51 Qiu Y, Luo X, Kan T, Zhang Y, Yu W, Wei Y, Shen N, Yi B, Jiang X. TGF-β upregulates miR-182 expression to promote gallbladder cancer metastasis by targeting CADM1. Mol Biosyst. 2014;10:679-685. [PMID: 24445397 DOI: 10.1039/c3mb70479c] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 5.4] [Reference Citation Analysis]
52 Cariati A, Piromalli E, Cetta F. Gallbladder cancers: associated conditions, histological types, prognosis, and prevention. Eur J Gastroenterol Hepatol. 2014;26:562-569. [PMID: 24614695 DOI: 10.1097/meg.0000000000000074] [Cited by in Crossref: 29] [Cited by in F6Publishing: 14] [Article Influence: 4.1] [Reference Citation Analysis]
53 Wasnik AP, Davenport MS, Kaza RK, Weadock WJ, Udager A, Keshavarzi N, Nan B, Maturen KE. Diagnostic accuracy of MDCT in differentiating gallbladder cancer from acute and xanthogranulomatous cholecystitis. Clin Imaging. 2018;50:223-228. [PMID: 29679780 DOI: 10.1016/j.clinimag.2018.04.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
54 Li M, Chen L, Qu Y, Sui F, Yang Q, Ji M, Shi B, Chen M, Hou P. Identification of MAP kinase pathways as therapeutic targets in gallbladder carcinoma using targeted parallel sequencing. Oncotarget 2017;8:36319-30. [PMID: 28422736 DOI: 10.18632/oncotarget.16751] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
55 Xu HL, Hsing AW, Vogtmann E, Chu LW, Cheng JR, Gao J, Tan YT, Wang BS, Shen MC, Gao YT. Variants in CCK and CCKAR genes to susceptibility to biliary tract cancers and stones: a population-based study in Shanghai, China. J Gastroenterol Hepatol. 2013;28:1476-1481. [PMID: 23701593 DOI: 10.1111/jgh.12278] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
56 Cao Y, Liang H, Zhang F, Luan Z, Zhao S, Wang XA, Liu S, Bao R, Shu Y, Ma Q, Zhu J, Liu Y. Prohibitin overexpression predicts poor prognosis and promotes cell proliferation and invasion through ERK pathway activation in gallbladder cancer. J Exp Clin Cancer Res 2016;35:68. [PMID: 27084680 DOI: 10.1186/s13046-016-0346-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
57 Gu X, Li B, Jiang M, Fang M, Ji J, Wang A, Wang M, Jiang X, Gao C. RNA sequencing reveals differentially expressed genes as potential diagnostic and prognostic indicators of gallbladder carcinoma. Oncotarget. 2015;6:20661-20671. [PMID: 25970782 DOI: 10.18632/oncotarget.3861] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
58 Maplanka C. Gallbladder Cancer, Treatment Failure and Relapses: the Peritoneum in Gallbladder Cancer. J Gastrointest Canc 2014;45:245-55. [DOI: 10.1007/s12029-014-9597-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
59 Zhu JQ, Han DD, Li XL, Kou JT, Fan H, He Q. Predictors of incidental gallbladder cancer in elderly patients. Hepatobiliary Pancreat Dis Int 2015;14:96-100. [PMID: 25655297 DOI: 10.1016/s1499-3872(14)60292-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
60 Yamaguchi J, Kaneoka Y, Maeda A, Takayama Y, Onoe S, Isogai M. Benefit of extended radical surgery for incidental gallbladder carcinoma. Surg Today 2016;46:453-9. [DOI: 10.1007/s00595-015-1198-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
61 Wang H, Zhan M, Liu Q, Wang J. Glycochenodeoxycholate promotes the metastasis of gallbladder cancer cells by inducing epithelial to mesenchymal transition via activation of SOCS3/JAK2/STAT3 signaling pathway. J Cell Physiol 2020;235:1615-23. [PMID: 31347168 DOI: 10.1002/jcp.29080] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
62 Lee W, Jeong C, Jang JY, Kim YH, Roh YH, Kim KW, Kang SH, Yoon MH, Seo HI, Yun SP, Park J, Jung B, Shin DH, Choi YI, Moon HH, Chu CW, Ryu JH, Yang K, Park YM, Hong S. Do hepatic-sided tumors require more extensive resection than peritoneal-sided tumors in patients with T2 gallbladder cancer? Results of a retrospective multicenter study. Surgery 2017;162:515-24. [DOI: 10.1016/j.surg.2017.05.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
63 Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol. 2014;6:99-109. [PMID: 24634588 DOI: 10.2147/clep.s37357.] [Reference Citation Analysis]
64 He XD, Li JJ, Liu W, Qu Q, Hong T, Xu XQ, Li BL, Wang Y, Zhao HT. Surgical procedure determination based on tumor-node-metastasis staging of gallbladder cancer. World J Gastroenterol 2015;21:4620-6. [PMID: 25914471 DOI: 10.3748/wjg.v21.i15.4620] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
65 Barreto SG, Dutt A, Chaudhary A. A genetic model for gallbladder carcinogenesis and its dissemination. Ann Oncol. 2014;25:1086-1097. [PMID: 24705974 DOI: 10.1093/annonc/mdu006] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
66 Xie Y, Jiang Y, Yang XB, Wang AQ, Zheng YC, Wan XS, Sang XT, Wang K, Zhang DD, Xu JJ, Li FG, Zhao HT. Response of BRCA1-mutated gallbladder cancer to olaparib: A case report. World J Gastroenterol 2016;22:10254-9. [PMID: 28028375 DOI: 10.3748/wjg.v22.i46.10254] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
67 Deng Y, Xu MF, Zhang F, Yu X, Zhang XW, Sun ZG, Wang S. Prognostic value of preoperative lymphocyte-to-monocyte ratio in gallbladder carcinoma patients and the establishment of a prognostic nomogram. Medicine (Baltimore) 2020;99:e21021. [PMID: 32756087 DOI: 10.1097/MD.0000000000021021] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
68 Yifan T, Zheyong L, Miaoqin C, Liang S, Xiujun C. A predictive model for survival of gallbladder adenocarcinoma. Surg Oncol 2018;27:365-72. [PMID: 30217289 DOI: 10.1016/j.suronc.2018.05.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
69 Zhang Y, Du P, Li Y, Zhu Q, Song X, Liu S, Hao J, Liu L, Liu F, Hu Y, Jiang L, Ma Q, Lu W, Liu Y. TASP1 Promotes Gallbladder Cancer Cell Proliferation and Metastasis by Up-regulating FAM49B via PI3K/AKT Pathway. Int J Biol Sci 2020;16:739-51. [PMID: 32071545 DOI: 10.7150/ijbs.40516] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
70 Zhang Y, Liu S, Wang L, Wu Y, Hao J, Wang Z, Lu W, Wang XA, Zhang F, Cao Y, Liang H, Li H, Ye Y, Ma Q, Zhao S, Shu Y, Bao R, Jiang L, Hu Y, Zhou J, Chen L, Liu Y. A novel PI3K/AKT signaling axis mediates Nectin-4-induced gallbladder cancer cell proliferation, metastasis and tumor growth. Cancer Lett 2016;375:179-89. [PMID: 26949052 DOI: 10.1016/j.canlet.2016.02.049] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 7.4] [Reference Citation Analysis]
71 Zhang Z, Zheng X, Li J, Duan J, Cui L, Yang L, Zhang L, Zhang Q, Wang X. Overexpression of UBR5 promotes tumor growth in gallbladder cancer via PTEN/PI3K/Akt signal pathway. J Cell Biochem 2019. [PMID: 30775814 DOI: 10.1002/jcb.28431] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
72 Inagaki C, Maeda D, Kimura A, Otsuru T, Iwagami Y, Nishida N, Sakai D, Shitotsuki R, Yachida S, Doki Y, Satoh T. Gallbladder cancer harboring ERBB2 mutation on the primary and metastatic site: A case report. World J Gastrointest Oncol 2019;11:761-7. [PMID: 31558980 DOI: 10.4251/wjgo.v11.i9.761] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
73 Wang Y, Hong Q, Wang J, Fang Y, Hu C. Downregulated expression of metastasis associated in colon cancer 1 (MACC1) reduces gallbladder cancer cell proliferation and invasion. Tumour Biol 2014;35:3771-8. [PMID: 24425103 DOI: 10.1007/s13277-013-1499-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
74 Kinugasa H, Nouso K, Ako S, Dohi C, Matsushita H, Matsumoto K, Kato H, Okada H. Liquid biopsy of bile for the molecular diagnosis of gallbladder cancer. Cancer Biol Ther. 2018;19:934-938. [PMID: 29580156 DOI: 10.1080/15384047.2018.1456604] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
75 Zemour J, Marty M, Lapuyade B, Collet D, Chiche L. Gallbladder tumor and pseudotumor: Diagnosis and management. Journal of Visceral Surgery 2014;151:289-300. [DOI: 10.1016/j.jviscsurg.2014.05.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 2.9] [Reference Citation Analysis]
76 Xu WY, Zhang HH, Yang XB, Bai Y, Lin JZ, Long JY, Xiong JP, Zhang JW, Sang XT, Zhao HT. Prognostic significance of combined preoperative fibrinogen and CA199 in gallbladder cancer patients. World J Gastroenterol. 2018;24:1451-1463. [PMID: 29632426 DOI: 10.3748/wjg.v24.i13.1451] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
77 Patkar S, Ostwal V, Ramaswamy A, Engineer R, Chopra S, Shetty N, Dusane R, Shrikhande SV, Goel M. Emerging role of multimodality treatment in gall bladder cancer: Outcomes following 510 consecutive resections in a tertiary referral center. J Surg Oncol 2018;117:372-9. [DOI: 10.1002/jso.24837] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]